Effects of Transcranial Direct Current Stimulation (tDCS) in Spoken and Written Production in Primary Progressive Aphasia (PPA) View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2013-2020

ABSTRACT

Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. Mild cognitive impairment (MCI) is slowly progressive decline in a single domain of cognition (e.g. language) not attributable to motor or sensory loss, without impediment of social or occupational function. MCI can be an early sign of neurodegenerative disease, or can be due to normal aging. When language is the prominent affected domain in MCI, the person may later meet criteria for PPA or may progress to the clinical syndrome of Alzheimer's dementia. Spelling, naming, and working memory (e.g. repetition) are among the language abilities affected early in the course of PPA or language-centered MCI, and different variants have distinct deficits in these domains. This research project investigates the behavioral and neuromodulatory effects of transcranial direct current stimulation (tDCS) during language therapy in PPA participants over time. Anodal tDCS targeting the left inferior frontal gyrus (IFG) administered in combination with language therapy is expected to be more beneficial when compared to language therapy alone. It will 1) improve language performance or decrease rate of decline, 2) have better-sustained effects at 2 weeks and 2 months post-treatment, and 3) produce generalization to untrained language items and some other cognitive functions. Resting-state fMRI, diffusion tensor imaging (DTI), and volumetric data are also collected to investigate changes in functional brain connectivity associated with tDCS in individuals with PPA. A better understanding of the therapeutic and neuromodulatory mechanisms of tDCS as an adjunct to language therapy in PPA may have a significant impact on the development of effective therapies for PPA and MCI, and may offer insight into ways of impeding neurodegeneration that may improve patients' quality of life, as well as extend their ability to work and manage their affairs. Detailed Description A. Evaluation Tasks Language Tasks: Participants will be administered baseline language and cognitive tasks, including 1 or more of the following, depending on their residual language and cognitive skills: a) writing to dictation b) oral spelling c) oral and written naming of pictures d) word-picture matching f) written and oral picture description g) digit span h) spatial span i) verbal learning j) grammatical sentence production k) oral word repetition l) sentence comprehension Quality of Life questionnaires: Participants will be administered standardized and non-standardized quality-of-life questionnaires before, after, and at follow-up intervals of each experimental period. The purpose of these questionnaires is to assess whether the proposed interventions have affected participants' well-being and the general quality of their life. B. Spoken and Written Word Production Therapy Interventions Individuals with PPA will receive spoken and written word production intervention tailored to their degree of deficit. Two interventions (basic and advanced) will be implemented, treating the main lexical retrieval deficits in PPA, in oral and written modalities. The goal of the combined interventions is to promote interaction between phonological and orthographic representations and processes in the remediation of lexical retrieval deficits that are prominent in all PPA subtypes. C. Assessment of Language Therapy Tasks: Follow-up assessment will probe all sets of trained phoneme-grapheme correspondences, words, or other stimuli (e.g. sentences) to identify whether or not the patient has retained knowledge of the trained items. Differences in baseline measures in pre- and post-therapy accuracy for phoneme-grapheme correspondences for each patient will be evaluated using the following: percentages of total number of points correct, arithmetic differences between percentage scores, and permutation tests (Pearson's chi-square test; Fisher's exact test). C. tDCS Methods: Participants will take part in 10-15 consecutive training sessions (3-5 per week), separated by 2 months. Anodal tDCS has typically been shown to up-regulate neuronal excitability and produce enhancement of behavioral performance. A Soterix-CT device will be delivering current at an intensity of 1-2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) for a maximum of 20 minutes in the tDCS groups and for a maximum of 30 seconds in the Sham group. For both interventions (tDCS and Sham) the electrical current will be increased in a ramp-like fashion at the onset of the stimulation eliciting a transient tingling sensation on the scalp that usually disappears over seconds.. D. Imaging Methods: Imaging will be performed at the beginning of enrollment, before and after each 12-to-15-day tDCS treatment, and at follow-up intervals for up to 8 time points per individual on a 3T Philips system, and will consist of resting-state fMRI (rsfMRI), MPRAGE, and diffusion tensor imaging (DTI). Each scanning session will last approximately 1 hour. E. Statistical Analyses: In the within-subject crossover protocol, each participant will be administered three experimental conditions: Control (natural progression), IFG tDCS+language (henceforth abbr. tDCS treatment) (word production) and sham tDCS+language (henceforth abbr. sham treatment). To achieve an accurate estimate of degeneration and rate of decline in each participant at their particular stage of the disease progression, each participant will first be enrolled in the control condition (natural progression), such that for the first 12 weeks they will not receive any therapy. Then the participant will receive either the tDCS treatment followed by sham, or vice versa. All analyses, behavioral and imaging, will be under the oversight of the study statisticians. F. Study duration and number of study visits required of research participants. Before any intervention, participants will be enrolled in a control condition for 12 weeks during which no therapy will be provided to enable us to assess their personal decline rate. After this period they will be randomly assigned to either sham or tDCS experimental conditions. After 1-3 weeks of tDCS application (3-5 sessions in a week, 10-15 sessions per stimulation site) there will be an interval of approximately 2 months and then we will implement the other two tDCS conditions in a within-subject cross-over design. Participants will be followed-up at 2-week and 2-month follow-up intervals. G. Blinding, including justification for blinding or not blinding the trial, if applicable. Participants will be blinded to the application of anodal or sham tDCS. To achieve blinding, all participants will be fitted with the tDCS electrodes placed over the left inferior frontal gyrus. The Soterix-CT device will be used for double-blinding purposes. H. Justification of why participants will not receive routine care or will have current therapy stopped Participation in this study will not disrupt any current care or therapy. I. Justification for inclusion of a placebo or non-treatment group All participants will undergo active and sham conditions, thus serving as their own control. J. Definition of treatment failure or participant removal criteria Participants will be removed from the study if they are unable to comply with task instructions or tolerate the tDCS procedure. K. Description of what happens to participants receiving therapy when study ends or if a participant's participation in the study ends prematurely When the study ends participants will continue to receive management with their neurologist as usual. If a patient's participation in the study ends prematurely s/he will still receive care as before. In sum, termination of the study or termination of participation in it will not affect regular therapy he or she may be receiving. L. Qualification of investigators: The PI and co-investigators have extensive research and clinical experience with all study tasks: behavioral language therapy (including spelling, naming, and repetition therapy. The investigators have arelady published a tDCS study on the behavioral results for the improvement of spelling abilities (Tsapkini et al., 2014). More... »

URL

https://clinicaltrials.gov/show/NCT02606422

Related SciGraph Publications

  • 2015-08. Treatment of Primary Progressive Aphasia in CURRENT TREATMENT OPTIONS IN NEUROLOGY
  • JSON-LD is the canonical representation for SciGraph data.

    TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

    [
      {
        "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
        "about": [
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3468", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }, 
          {
            "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3053", 
            "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
            "type": "DefinedTerm"
          }
        ], 
        "description": "Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. Mild cognitive impairment (MCI) is slowly progressive decline in a single domain of cognition (e.g. language) not attributable to motor or sensory loss, without impediment of social or occupational function. MCI can be an early sign of neurodegenerative disease, or can be due to normal aging. When language is the prominent affected domain in MCI, the person may later meet criteria for PPA or may progress to the clinical syndrome of Alzheimer's dementia. Spelling, naming, and working memory (e.g. repetition) are among the language abilities affected early in the course of PPA or language-centered MCI, and different variants have distinct deficits in these domains. This research project investigates the behavioral and neuromodulatory effects of transcranial direct current stimulation (tDCS) during language therapy in PPA participants over time. Anodal tDCS targeting the left inferior frontal gyrus (IFG) administered in combination with language therapy is expected to be more beneficial when compared to language therapy alone. It will 1) improve language performance or decrease rate of decline, 2) have better-sustained effects at 2 weeks and 2 months post-treatment, and 3) produce generalization to untrained language items and some other cognitive functions. Resting-state fMRI, diffusion tensor imaging (DTI), and volumetric data are also collected to investigate changes in functional brain connectivity associated with tDCS in individuals with PPA. A better understanding of the therapeutic and neuromodulatory mechanisms of tDCS as an adjunct to language therapy in PPA may have a significant impact on the development of effective therapies for PPA and MCI, and may offer insight into ways of impeding neurodegeneration that may improve patients' quality of life, as well as extend their ability to work and manage their affairs.\n\nDetailed Description\nA. Evaluation Tasks Language Tasks: Participants will be administered baseline language and cognitive tasks, including 1 or more of the following, depending on their residual language and cognitive skills: a) writing to dictation b) oral spelling c) oral and written naming of pictures d) word-picture matching f) written and oral picture description g) digit span h) spatial span i) verbal learning j) grammatical sentence production k) oral word repetition l) sentence comprehension Quality of Life questionnaires: Participants will be administered standardized and non-standardized quality-of-life questionnaires before, after, and at follow-up intervals of each experimental period. The purpose of these questionnaires is to assess whether the proposed interventions have affected participants' well-being and the general quality of their life. B. Spoken and Written Word Production Therapy Interventions Individuals with PPA will receive spoken and written word production intervention tailored to their degree of deficit. Two interventions (basic and advanced) will be implemented, treating the main lexical retrieval deficits in PPA, in oral and written modalities. The goal of the combined interventions is to promote interaction between phonological and orthographic representations and processes in the remediation of lexical retrieval deficits that are prominent in all PPA subtypes. C. Assessment of Language Therapy Tasks: Follow-up assessment will probe all sets of trained phoneme-grapheme correspondences, words, or other stimuli (e.g. sentences) to identify whether or not the patient has retained knowledge of the trained items. Differences in baseline measures in pre- and post-therapy accuracy for phoneme-grapheme correspondences for each patient will be evaluated using the following: percentages of total number of points correct, arithmetic differences between percentage scores, and permutation tests (Pearson's chi-square test; Fisher's exact test). C. tDCS Methods: Participants will take part in 10-15 consecutive training sessions (3-5 per week), separated by 2 months. Anodal tDCS has typically been shown to up-regulate neuronal excitability and produce enhancement of behavioral performance. A Soterix-CT device will be delivering current at an intensity of 1-2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) for a maximum of 20 minutes in the tDCS groups and for a maximum of 30 seconds in the Sham group. For both interventions (tDCS and Sham) the electrical current will be increased in a ramp-like fashion at the onset of the stimulation eliciting a transient tingling sensation on the scalp that usually disappears over seconds.. D. Imaging Methods: Imaging will be performed at the beginning of enrollment, before and after each 12-to-15-day tDCS treatment, and at follow-up intervals for up to 8 time points per individual on a 3T Philips system, and will consist of resting-state fMRI (rsfMRI), MPRAGE, and diffusion tensor imaging (DTI). Each scanning session will last approximately 1 hour. E. Statistical Analyses: In the within-subject crossover protocol, each participant will be administered three experimental conditions: Control (natural progression), IFG tDCS+language (henceforth abbr. tDCS treatment) (word production) and sham tDCS+language (henceforth abbr. sham treatment). To achieve an accurate estimate of degeneration and rate of decline in each participant at their particular stage of the disease progression, each participant will first be enrolled in the control condition (natural progression), such that for the first 12 weeks they will not receive any therapy. Then the participant will receive either the tDCS treatment followed by sham, or vice versa. All analyses, behavioral and imaging, will be under the oversight of the study statisticians. F. Study duration and number of study visits required of research participants. Before any intervention, participants will be enrolled in a control condition for 12 weeks during which no therapy will be provided to enable us to assess their personal decline rate. After this period they will be randomly assigned to either sham or tDCS experimental conditions. After 1-3 weeks of tDCS application (3-5 sessions in a week, 10-15 sessions per stimulation site) there will be an interval of approximately 2 months and then we will implement the other two tDCS conditions in a within-subject cross-over design. Participants will be followed-up at 2-week and 2-month follow-up intervals. G. Blinding, including justification for blinding or not blinding the trial, if applicable. Participants will be blinded to the application of anodal or sham tDCS. To achieve blinding, all participants will be fitted with the tDCS electrodes placed over the left inferior frontal gyrus. The Soterix-CT device will be used for double-blinding purposes. H. Justification of why participants will not receive routine care or will have current therapy stopped Participation in this study will not disrupt any current care or therapy. I. Justification for inclusion of a placebo or non-treatment group All participants will undergo active and sham conditions, thus serving as their own control. J. Definition of treatment failure or participant removal criteria Participants will be removed from the study if they are unable to comply with task instructions or tolerate the tDCS procedure. K. Description of what happens to participants receiving therapy when study ends or if a participant's participation in the study ends prematurely When the study ends participants will continue to receive management with their neurologist as usual. If a patient's participation in the study ends prematurely s/he will still receive care as before. In sum, termination of the study or termination of participation in it will not affect regular therapy he or she may be receiving. L. Qualification of investigators: The PI and co-investigators have extensive research and clinical experience with all study tasks: behavioral language therapy (including spelling, naming, and repetition therapy. The investigators have arelady published a tDCS study on the behavioral results for the improvement of spelling abilities (Tsapkini et al., 2014).", 
        "endDate": "2020-05-01T00:00:00Z", 
        "id": "sg:clinicaltrial.NCT02606422", 
        "keywords": [
          "transcranial direct current stimulation", 
          "tDCS", 
          "spoken", 
          "Primary progressive aphasia", 
          "neurodegenerative disease", 
          "language ability", 
          "mild cognitive impairment", 
          "progressive decline", 
          "single domain", 
          "cognition", 
          "language", 
          "motor", 
          "sensory loss", 
          "impediment", 
          "Social", 
          "early sign", 
          "normal aging", 
          "domain", 
          "criterion", 
          "progress", 
          "clinical syndrome", 
          "Alzheimer's", 
          "dementia", 
          "spelling", 
          "naming", 
          "memory", 
          "repetition", 
          "different variant", 
          "deficit", 
          "research project", 
          "neuromodulatory effect", 
          "Language Therapy", 
          "inferior frontal gyrus", 
          "language performance", 
          "decrease rate", 
          "decline", 
          "sustained effect", 
          "post-treatment", 
          "generalization", 
          "cognitive function", 
          "resting-state", 
          "diffusion tensor imaging", 
          "volumetric data", 
          "brain connectivity", 
          "individual", 
          "good understanding", 
          "adjunct", 
          "significant impact", 
          "development", 
          "effective therapy", 
          "neurodegeneration", 
          "patient quality", 
          "life", 
          "affair", 
          "language task", 
          "baseline", 
          "cognitive task", 
          "cognitive skill", 
          "picture", 
          "digit", 
          "span", 
          "sentence production", 
          "sentence comprehension", 
          "quality of life", 
          "questionnaire", 
          "follow-up interval", 
          "experimental period", 
          "intervention", 
          "well-being", 
          "general quality", 
          "word production", 
          "lexical retrieval", 
          "modality", 
          "combined intervention", 
          "representation", 
          "remediation", 
          "follow-up assessment", 
          "probe", 
          "correspondence", 
          "stimulus", 
          "sentence", 
          "patient", 
          "difference", 
          "baseline measure", 
          "post-therapy", 
          "total number", 
          "score", 
          "permutation", 
          "Pearson's", 
          "chi-square", 
          "Fisher's", 
          "training session", 
          "neuronal excitability", 
          "enhancement", 
          "behavioral performance", 
          "CT", 
          "intensity", 
          "current density", 
          "total charge", 
          "maximum", 
          "sham", 
          "fashion", 
          "onset", 
          "stimulation", 
          "sensation", 
          "scalp", 
          "imaging method", 
          "imaging", 
          "beginning", 
          "enrollment", 
          "time point", 
          "Philip", 
          "scanning session", 
          "statistical analysis", 
          "within-subject", 
          "experimental condition", 
          "control", 
          "natural progression", 
          "current", 
          "placebo", 
          "accurate estimate", 
          "degeneration", 
          "particular stage", 
          "disease progression", 
          "control condition", 
          "therapy", 
          "oversight", 
          "statistician", 
          "study duration", 
          "study visit", 
          "research participant", 
          "period", 
          "session", 
          "stimulation site", 
          "interval", 
          "followed-up", 
          "blinding", 
          "justification", 
          "trial", 
          "routine care", 
          "current therapy", 
          "participation", 
          "current care", 
          "inclusion", 
          "treatment group", 
          "condition", 
          "own control", 
          "definition", 
          "treatment failure", 
          "task", 
          "study end", 
          "management", 
          "neurologist", 
          "care", 
          "sum", 
          "termination", 
          "qualification", 
          "co-investigators", 
          "extensive research", 
          "behavioral result", 
          "improvement"
        ], 
        "name": "Effects of Transcranial Direct Current Stimulation (tDCS) in Spoken and Written Production in Primary Progressive Aphasia (PPA)", 
        "sameAs": [
          "https://app.dimensions.ai/details/clinical_trial/NCT02606422"
        ], 
        "sdDataset": "clinical_trials", 
        "sdDatePublished": "2019-03-07T15:26", 
        "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
        "sdPublisher": {
          "name": "Springer Nature - SN SciGraph project", 
          "type": "Organization"
        }, 
        "sdSource": "file:///pack/app/us_ct_data_00020.json", 
        "sponsor": [
          {
            "id": "https://www.grid.ac/institutes/grid.94365.3d", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.21107.35", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.411935.b", 
            "type": "Organization"
          }, 
          {
            "id": "https://www.grid.ac/institutes/grid.214431.1", 
            "type": "Organization"
          }
        ], 
        "startDate": "2013-04-01T00:00:00Z", 
        "subjectOf": [
          {
            "id": "sg:pub.10.1007/s11940-015-0362-5", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1006061649", 
              "https://doi.org/10.1007/s11940-015-0362-5"
            ], 
            "type": "CreativeWork"
          }, 
          {
            "id": "https://doi.org/10.1080/02687038.2014.930410", 
            "sameAs": [
              "https://app.dimensions.ai/details/publication/pub.1030691481"
            ], 
            "type": "CreativeWork"
          }
        ], 
        "type": "MedicalStudy", 
        "url": "https://clinicaltrials.gov/show/NCT02606422"
      }
    ]
     

    Download the RDF metadata as:  json-ld nt turtle xml License info

    HOW TO GET THIS DATA PROGRAMMATICALLY:

    JSON-LD is a popular format for linked data which is fully compatible with JSON.

    curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02606422'

    N-Triples is a line-based linked data format ideal for batch operations.

    curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02606422'

    Turtle is a human-readable linked data format.

    curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02606422'

    RDF/XML is a standard XML format for linked data.

    curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02606422'


     

    This table displays all metadata directly associated to this object as RDF triples.

    196 TRIPLES      16 PREDICATES      182 URIs      170 LITERALS      1 BLANK NODES

    Subject Predicate Object
    1 sg:clinicaltrial.NCT02606422 schema:about anzsrc-for:3053
    2 anzsrc-for:3468
    3 schema:description Primary progressive aphasia (PPA) is a neurodegenerative disease that affects first and foremost language abilities. Mild cognitive impairment (MCI) is slowly progressive decline in a single domain of cognition (e.g. language) not attributable to motor or sensory loss, without impediment of social or occupational function. MCI can be an early sign of neurodegenerative disease, or can be due to normal aging. When language is the prominent affected domain in MCI, the person may later meet criteria for PPA or may progress to the clinical syndrome of Alzheimer's dementia. Spelling, naming, and working memory (e.g. repetition) are among the language abilities affected early in the course of PPA or language-centered MCI, and different variants have distinct deficits in these domains. This research project investigates the behavioral and neuromodulatory effects of transcranial direct current stimulation (tDCS) during language therapy in PPA participants over time. Anodal tDCS targeting the left inferior frontal gyrus (IFG) administered in combination with language therapy is expected to be more beneficial when compared to language therapy alone. It will 1) improve language performance or decrease rate of decline, 2) have better-sustained effects at 2 weeks and 2 months post-treatment, and 3) produce generalization to untrained language items and some other cognitive functions. Resting-state fMRI, diffusion tensor imaging (DTI), and volumetric data are also collected to investigate changes in functional brain connectivity associated with tDCS in individuals with PPA. A better understanding of the therapeutic and neuromodulatory mechanisms of tDCS as an adjunct to language therapy in PPA may have a significant impact on the development of effective therapies for PPA and MCI, and may offer insight into ways of impeding neurodegeneration that may improve patients' quality of life, as well as extend their ability to work and manage their affairs. Detailed Description A. Evaluation Tasks Language Tasks: Participants will be administered baseline language and cognitive tasks, including 1 or more of the following, depending on their residual language and cognitive skills: a) writing to dictation b) oral spelling c) oral and written naming of pictures d) word-picture matching f) written and oral picture description g) digit span h) spatial span i) verbal learning j) grammatical sentence production k) oral word repetition l) sentence comprehension Quality of Life questionnaires: Participants will be administered standardized and non-standardized quality-of-life questionnaires before, after, and at follow-up intervals of each experimental period. The purpose of these questionnaires is to assess whether the proposed interventions have affected participants' well-being and the general quality of their life. B. Spoken and Written Word Production Therapy Interventions Individuals with PPA will receive spoken and written word production intervention tailored to their degree of deficit. Two interventions (basic and advanced) will be implemented, treating the main lexical retrieval deficits in PPA, in oral and written modalities. The goal of the combined interventions is to promote interaction between phonological and orthographic representations and processes in the remediation of lexical retrieval deficits that are prominent in all PPA subtypes. C. Assessment of Language Therapy Tasks: Follow-up assessment will probe all sets of trained phoneme-grapheme correspondences, words, or other stimuli (e.g. sentences) to identify whether or not the patient has retained knowledge of the trained items. Differences in baseline measures in pre- and post-therapy accuracy for phoneme-grapheme correspondences for each patient will be evaluated using the following: percentages of total number of points correct, arithmetic differences between percentage scores, and permutation tests (Pearson's chi-square test; Fisher's exact test). C. tDCS Methods: Participants will take part in 10-15 consecutive training sessions (3-5 per week), separated by 2 months. Anodal tDCS has typically been shown to up-regulate neuronal excitability and produce enhancement of behavioral performance. A Soterix-CT device will be delivering current at an intensity of 1-2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) for a maximum of 20 minutes in the tDCS groups and for a maximum of 30 seconds in the Sham group. For both interventions (tDCS and Sham) the electrical current will be increased in a ramp-like fashion at the onset of the stimulation eliciting a transient tingling sensation on the scalp that usually disappears over seconds.. D. Imaging Methods: Imaging will be performed at the beginning of enrollment, before and after each 12-to-15-day tDCS treatment, and at follow-up intervals for up to 8 time points per individual on a 3T Philips system, and will consist of resting-state fMRI (rsfMRI), MPRAGE, and diffusion tensor imaging (DTI). Each scanning session will last approximately 1 hour. E. Statistical Analyses: In the within-subject crossover protocol, each participant will be administered three experimental conditions: Control (natural progression), IFG tDCS+language (henceforth abbr. tDCS treatment) (word production) and sham tDCS+language (henceforth abbr. sham treatment). To achieve an accurate estimate of degeneration and rate of decline in each participant at their particular stage of the disease progression, each participant will first be enrolled in the control condition (natural progression), such that for the first 12 weeks they will not receive any therapy. Then the participant will receive either the tDCS treatment followed by sham, or vice versa. All analyses, behavioral and imaging, will be under the oversight of the study statisticians. F. Study duration and number of study visits required of research participants. Before any intervention, participants will be enrolled in a control condition for 12 weeks during which no therapy will be provided to enable us to assess their personal decline rate. After this period they will be randomly assigned to either sham or tDCS experimental conditions. After 1-3 weeks of tDCS application (3-5 sessions in a week, 10-15 sessions per stimulation site) there will be an interval of approximately 2 months and then we will implement the other two tDCS conditions in a within-subject cross-over design. Participants will be followed-up at 2-week and 2-month follow-up intervals. G. Blinding, including justification for blinding or not blinding the trial, if applicable. Participants will be blinded to the application of anodal or sham tDCS. To achieve blinding, all participants will be fitted with the tDCS electrodes placed over the left inferior frontal gyrus. The Soterix-CT device will be used for double-blinding purposes. H. Justification of why participants will not receive routine care or will have current therapy stopped Participation in this study will not disrupt any current care or therapy. I. Justification for inclusion of a placebo or non-treatment group All participants will undergo active and sham conditions, thus serving as their own control. J. Definition of treatment failure or participant removal criteria Participants will be removed from the study if they are unable to comply with task instructions or tolerate the tDCS procedure. K. Description of what happens to participants receiving therapy when study ends or if a participant's participation in the study ends prematurely When the study ends participants will continue to receive management with their neurologist as usual. If a patient's participation in the study ends prematurely s/he will still receive care as before. In sum, termination of the study or termination of participation in it will not affect regular therapy he or she may be receiving. L. Qualification of investigators: The PI and co-investigators have extensive research and clinical experience with all study tasks: behavioral language therapy (including spelling, naming, and repetition therapy. The investigators have arelady published a tDCS study on the behavioral results for the improvement of spelling abilities (Tsapkini et al., 2014).
    4 schema:endDate 2020-05-01T00:00:00Z
    5 schema:keywords Alzheimer's
    6 CT
    7 Fisher's
    8 Language Therapy
    9 Pearson's
    10 Philip
    11 Primary progressive aphasia
    12 Social
    13 accurate estimate
    14 adjunct
    15 affair
    16 baseline
    17 baseline measure
    18 beginning
    19 behavioral performance
    20 behavioral result
    21 blinding
    22 brain connectivity
    23 care
    24 chi-square
    25 clinical syndrome
    26 co-investigators
    27 cognition
    28 cognitive function
    29 cognitive skill
    30 cognitive task
    31 combined intervention
    32 condition
    33 control
    34 control condition
    35 correspondence
    36 criterion
    37 current
    38 current care
    39 current density
    40 current therapy
    41 decline
    42 decrease rate
    43 deficit
    44 definition
    45 degeneration
    46 dementia
    47 development
    48 difference
    49 different variant
    50 diffusion tensor imaging
    51 digit
    52 disease progression
    53 domain
    54 early sign
    55 effective therapy
    56 enhancement
    57 enrollment
    58 experimental condition
    59 experimental period
    60 extensive research
    61 fashion
    62 follow-up assessment
    63 follow-up interval
    64 followed-up
    65 general quality
    66 generalization
    67 good understanding
    68 imaging
    69 imaging method
    70 impediment
    71 improvement
    72 inclusion
    73 individual
    74 inferior frontal gyrus
    75 intensity
    76 interval
    77 intervention
    78 justification
    79 language
    80 language ability
    81 language performance
    82 language task
    83 lexical retrieval
    84 life
    85 management
    86 maximum
    87 memory
    88 mild cognitive impairment
    89 modality
    90 motor
    91 naming
    92 natural progression
    93 neurodegeneration
    94 neurodegenerative disease
    95 neurologist
    96 neuromodulatory effect
    97 neuronal excitability
    98 normal aging
    99 onset
    100 oversight
    101 own control
    102 participation
    103 particular stage
    104 patient
    105 patient quality
    106 period
    107 permutation
    108 picture
    109 placebo
    110 post-therapy
    111 post-treatment
    112 probe
    113 progress
    114 progressive decline
    115 qualification
    116 quality of life
    117 questionnaire
    118 remediation
    119 repetition
    120 representation
    121 research participant
    122 research project
    123 resting-state
    124 routine care
    125 scalp
    126 scanning session
    127 score
    128 sensation
    129 sensory loss
    130 sentence
    131 sentence comprehension
    132 sentence production
    133 session
    134 sham
    135 significant impact
    136 single domain
    137 span
    138 spelling
    139 spoken
    140 statistical analysis
    141 statistician
    142 stimulation
    143 stimulation site
    144 stimulus
    145 study duration
    146 study end
    147 study visit
    148 sum
    149 sustained effect
    150 tDCS
    151 task
    152 termination
    153 therapy
    154 time point
    155 total charge
    156 total number
    157 training session
    158 transcranial direct current stimulation
    159 treatment failure
    160 treatment group
    161 trial
    162 volumetric data
    163 well-being
    164 within-subject
    165 word production
    166 schema:name Effects of Transcranial Direct Current Stimulation (tDCS) in Spoken and Written Production in Primary Progressive Aphasia (PPA)
    167 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02606422
    168 schema:sdDatePublished 2019-03-07T15:26
    169 schema:sdLicense https://scigraph.springernature.com/explorer/license/
    170 schema:sdPublisher Nc25aae406283440a8c675c0509639cac
    171 schema:sponsor https://www.grid.ac/institutes/grid.21107.35
    172 https://www.grid.ac/institutes/grid.214431.1
    173 https://www.grid.ac/institutes/grid.411935.b
    174 https://www.grid.ac/institutes/grid.94365.3d
    175 schema:startDate 2013-04-01T00:00:00Z
    176 schema:subjectOf sg:pub.10.1007/s11940-015-0362-5
    177 https://doi.org/10.1080/02687038.2014.930410
    178 schema:url https://clinicaltrials.gov/show/NCT02606422
    179 sgo:license sg:explorer/license/
    180 sgo:sdDataset clinical_trials
    181 rdf:type schema:MedicalStudy
    182 Nc25aae406283440a8c675c0509639cac schema:name Springer Nature - SN SciGraph project
    183 rdf:type schema:Organization
    184 anzsrc-for:3053 schema:inDefinedTermSet anzsrc-for:
    185 rdf:type schema:DefinedTerm
    186 anzsrc-for:3468 schema:inDefinedTermSet anzsrc-for:
    187 rdf:type schema:DefinedTerm
    188 sg:pub.10.1007/s11940-015-0362-5 schema:sameAs https://app.dimensions.ai/details/publication/pub.1006061649
    189 https://doi.org/10.1007/s11940-015-0362-5
    190 rdf:type schema:CreativeWork
    191 https://doi.org/10.1080/02687038.2014.930410 schema:sameAs https://app.dimensions.ai/details/publication/pub.1030691481
    192 rdf:type schema:CreativeWork
    193 https://www.grid.ac/institutes/grid.21107.35 schema:Organization
    194 https://www.grid.ac/institutes/grid.214431.1 schema:Organization
    195 https://www.grid.ac/institutes/grid.411935.b schema:Organization
    196 https://www.grid.ac/institutes/grid.94365.3d schema:Organization
     




    Preview window. Press ESC to close (or click here)


    ...